Drug Profile


Alternative Names: Dupixent; REGN 668; SAR 231893

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor type I antagonists; Interleukin 4 receptor type II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Phase III Asthma; Nasal polyps
  • Phase II Eosinophilic oesophagitis
  • Phase I Allergic asthma

Most Recent Events

  • 20 Apr 2017 Regeneron Pharmaceuticals and Sanofi plans a phase I trial for Allergic asthma (Monotherapy, Combination therapy) (NCT03112577)
  • 07 Apr 2017 Phase-III clinical trials in Atopic dermatitis (In adolescents) in USA (SC) (NCT03054428)
  • 01 Apr 2017 Phase-I clinical trials in Allergic asthma (Combination therapy) (unspecified route) (NCT03112577)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top